Nearly 1000 research papers have been published supporting the utility of Procalcitonin as an early diagnostic marker and a prognostic marker for detecting and monitoring bacterial sepsis.
Less than 0.5 ng/ml (age specific in neonates between 0 – 72 hours from the time of birth).More than 300 plus referral hospitals in India are using Procalcitonin to detect Sepsis and as a prognostic marker for monitoring sepsis.Procalcitonin is available exclusively from Brahms through CPC in the following formats
The following are the assays which can be performed with ease on Kryptor compact:
Trisomy 21 or Down’s Syndrome is one of the most common genetic abnormalities affecting 1 in every 700 births worldwide. The risks of chromosomal defects like Trisomy 21 increases with maternal age, but decreases with gestational age, since foetuses with chromosomal defects are more likely to die in-utero than unaffected foetuses. But the majority of babies with Down’s Syndrome are born to healthy young parents without any known risk.
Invasive testing for chromosomal abnormalities is associated with a certain risk of miscarriage of about 1%. Non-invasive testing – with a combination of biochemical markers and nuchal translucency measurement in the 1st trimester of pregnancy or with biochemical markers alone in the 2nd trimester of pregnancy – allows the group of mothers under the age of 35 years – usually considered to be at low risk – to assess their individual risk without having to submit to invasive testing.
A responsible risk assessment requires high precision and accuracy in the measurement of the biochemical markers, as well as for the measurement of the Nuchal Translucency (NT). For the biochemical markers, KRYPTOR fulfils these requirements in an exceptional way, making KRYPTOR the instrument of choice for 1st and 2nd trimester screening.